Episodes: 165
Frequency: Irregular
Rating: 4.8/5.0
Estimated listeners: 10k-100k
Gender skew: Neutral
Location: USA
Instagram: 1.0k followers
30s Ad: 593 - 730, 60s Ad: 707 - 844
Dan Weissmann - Created, hosted, and produced An Arm and a Leg. A seasoned journalist focused on healthcare costs and the policies/system incentives behind medical pricing and access, co-produced with KFF Health N...
Linda Michaels - Tech Intermediaries In Therapy Workflows, Privacy/confidentiality Risks From Recording/transcription, And Policy Efforts To Encourage More Therapists To Stay In-network
Al Engelberg - History And Incentives Of The Drug Patent System, Generic Drug Market Dynamics, And Proposed Fixes To High Drug Prices
The Chatbot Will See You Now: Big Tech In Therapy (from Organized Money)
May 21, 2026
One place you might assume is safe from prying ears is your therapy session. But as more therapists struggle to negotiate with insurers, they’re turning to tech middlemen like BetterHelp and Headway that promise to take care of the insurance admin and match them with patients. And these companies are sometimes recording and transcribing your sessions — and then turning around and sharing that data with social media companies and investors. And there are concerns that t...
The Supreme Court case that could slow generic drugs
April 27, 2026
It’s a case you’ve (probably) never heard of: This week, the Supreme Court is hearing oral arguments in Hikma v. Amarin — a legal battle that could impact how much you ultimately pay for prescription drugs. Here’s why the case matters: As soon as a generic version of a brand-name drug comes to market, its price typically drops by half. Within 10 years, by more than 75%. Meaning: the sooner we have access to generics, the less we pay at the pharmacy counter. ...
Why drugs cost so much, 101: Medicine monopolies
April 09, 2026
We’re always asking: Why do drugs cost so freaking much? And it’s a complicated question. There are a bunch of reasons — to be sure. But in our reporting over the years, like our stories on insulin and tuberculosis drugs, experts cited one big reason over and over again: The pharmaceutical industry wages sophisticated legal battles to keep monopoly control over their best selling, most lucrative drugs — blocking generic competition, and increasing thei...
Try us risk free with a FREE 3 days trial.
Join hundreds of PR teams using Podseeker to pitch and land bookings